Diabetes mellitus is associated with a higher incidence of certain infections, including fungal infections like rhinocerebral zygomycosis (RCZ) and cutaneous candidosis. As the pathophysiology of increased susceptibility to infection of diabetic patients is very complex, a general therapeutic approach is not existing yet. Appropriate diabetes control remains as the best preventive measure. Nevertheless, effective drug therapy is very often required.Fluconazole has proven efficacy in prophylaxis, treatment and suppressive therapy of both systemic and superficial fungal infections, especially in candidosis and cryptococcosis. Therefore it is used routinely against fungal infections in diabetes (FID).Clinical efficacy of fluconazole against cutaeneous candidosis, oropharyngeal candidosis (OPC) and vulvovaginal candidosis (WC) has been confirmed in more than 100 studies, involving more than 10.000 patients (pts). The overall success rate is 90%, with a mean dosage of 100-200 mg/d. In severe cases, e.g. in OPC in late- stage AIDS pts or in recurrent WC, higher dosages of up to 800mg/d may be required.In the treatment of RCZ, therapeutic experience with fluconazole is limited(1,2). Four diabetic pts have been treated with dosages of 200-300 mg/d and all of them recovered. Nevertheless, treatment of RCZ should include surgical debridement combined with aggressive antifungal therapy.In conclusion, proven efficacy and the excellent safety profile justify the routine use of fluconazole in the treatment of FID.
Full conference title:
5th Congress of the European-Confederation-of-Medical-History/ 33th Scientific Meeting of the Deutschsprachige-Mykologische- Gesellschaft-EV
- ECMM 5th (1999)